Black Rock Inc. Cellectar Biosciences, Inc. Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$3.36 - $6.37 $1.93 Million - $3.66 Million	-574,451 Closed	0 $0
Q2 2022 Aug 12, 2022	SELL	$3.5 - $6.9 $483,798 - $953,773	-138,228 Reduced 19.4%	574,451 $232,000
Q1 2022 May 12, 2022	SELL	$4.6 - $7.8 $32,002 - $54,264	-6,957 Reduced 0.97%	712,679 $489,000
Q4 2021 Feb 10, 2022	BUY	$6.1 - $10.2 $41,297 - $69,054	6,770 Added 0.95%	719,636 $478,000
Q3 2021 Nov 09, 2021	SELL	$8.2 - $12.4 $25,354 - $38,340	-3,092 Reduced 0.43%	712,866 $659,000
Q2 2021 Aug 11, 2021	BUY	$11.8 - $18.2 $8.45 Million - $13 Million	715,958 New	715,958 $852,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $9.6M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.